Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity | AZBio
![Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi](https://www.sanofi.com/dam/jcr:562fe9e8-c2f0-4ad1-ab67-a95d3f3eeb98/KeyFigures_Employees.jpg)
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi
![Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm | EuropaWire.eu | The European Union's press release distribution & Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm | EuropaWire.eu | The European Union's press release distribution &](https://news.europawire.eu/wp-content/uploads/2021/12/ORIGIMM.jpg)
Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm | EuropaWire.eu | The European Union's press release distribution &
![Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi](https://i.ytimg.com/vi/SCdP19SKvo8/maxresdefault.jpg)